Pulmonary Arterial Pressure Above 30 mmHg Linked to Increased...
WEBby Iqra Mumal, MSc July 8, 2019. An estimated right ventricular systolic pressure (eRVSP) — a measure of the pressure inside the artery that supplies blood to the lungs (pulmonary artery) — greater than 30.0 mmHg is related to an increased risk of mortality in patients with pulmonary hypertension (PH), according to a new Australian study.
For PAH Treatment, Mylan Launches Tadalafil Tablets, 1st Generic...
WEBAug 22, 2018 · Mylan Announces U.S. Launch of 20 mg Tadalafil Tablets, 1st Generic of Adcirca for PAH Treatment. by Iqra Mumal, MSc August 22, 2018. Mylan recently introduced a formulation of 20 mg tadalafil tablets, the first generic version of Eli Lilly ‘s Adcirca, in the United States for patients with pulmonary arterial hypertension (PAH).
Tyvaso Becomes 1st PH-ILD Treatment Approved in US
WEBApr 1, 2021 · 462488992/Shutterstock. Tyvaso (inhaled treprostinil) has become the first treatment approved in the U.S. for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The U.S. Food and Drug Administration (FDA) approved Tyvaso, developed by United Therapeutics, to improve exercise ability in …
8 Fun Facts About Lungs – Pulmonary Hypertension News
WEBDec 20, 2017 · 7. Children and women breathe faster. Children and women have a higher breathing rate than men. 8. Humans exhale up to 17.5 mililiters of water per hour. MORE: Check out how you can increase your lung capacity with breathing exercises. Pulmonary Hypertension News is strictly a news and information website about the disease.
New PAH Drug from Actelion Approved by FDA – Pulmonary...
WEBJan 5, 2016 · by Margarida Azevedo, MSc January 5, 2016. According to a recent announcement, the United States Food and Drug Administration (FDA) approved Actelion Pharmaceuticals’ Uptravi (selexipag) tablets for the treatment of adult patients with pulmonary arterial hypertension (PAH) to delay disease progression and reduce the risk of hospitalization ...
Aria Raises $31M for Planned Study of Balloon Implant to Treat PAH
WEBMar 2, 2020 · Aria CV announced the end of a funding round that will be used to finance a feasibility study of its medical device, the Pulmonary Hypertension System (Aria CV PH System), in people with pulmonary arterial hypertension (PAH) in the U.S. The series B round, which raised $31 million, was led by Xeraya Capital. “Aria …
FDA Names SoniVie’s TIVUS System a Breakthrough Device for PAH
WEBSep 11, 2019 · FDA Grants Breakthrough Device Status to SoniVie’s TIVUS System for PAH. by Joana Carvalho, PhD September 11, 2019. The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough device to SoniVie’s Therapeutic Intra-Vascular Ultrasound (TIVUS) System for the treatment of people with pulmonary arterial hypertension ...
Pulmonary Venous Hypertension (PVH)
WEBJun 29, 2021 · The symptoms of PVH are similar to those of other types of PH. Patients may experience shortness of breath, tiredness, chest pain, and fainting during normal activity, but are comfortable at rest. Swelling of the legs and ankles also may occur. Patients with PVH often have sleep apnea, which is repeated stops and starts of …
Living PHearlessly is goal for PH Awareness Month and beyond
WEBNov 1, 2023 · Leading these efforts is the Pulmonary Hypertension Association (PHA), the country’s oldest and largest nonprofit dedicated to the PH community. The PHA’s mission is to improve the lives of those affected by the chronic disease — during awareness month and beyond — with a focus on research and extending patients’ survival.. This year, the PHA is launching a “Live PHearlessly ...
First Patient Enrolled in REBUILD Trial of INOpulse for...
WEBDec 4, 2020 · Top-line data from a previous Phase 2/3 trial, called iNO-PF (NCT03267108), showed that when given over four months at a dose of 45 mcg/kg ideal body weight/per hour (mcg/kg IBW/hr), INOpulse was able to improve patients’ moderate-to-vigorous physical activity (MVPA) by 20% compared to a placebo.. Treatment also improved participants’ self-reported quality of life, lowered their shortness ...